Patents Assigned to H. Lundbeck A/S
  • Combination of brexpiprazole and nalmefene and use thereof for treating substance-related disorders
    Patent number: 11642341
    Abstract: A medicament comprising (I) brexpiprazole or a pharmaceutically acceptable salt thereof, and (II) nalmefene or a pharmaceutically acceptable salt thereof in combination, wherein brexpiprazole or a pharmaceutically acceptable salt thereof, and nalmefene or a pharmaceutically acceptable salt thereof are contained in a single preparation, or a pharmaceutical composition containing brexpiprazole or a pharmaceutically acceptable salt thereof and a pharmaceutical composition containing nalmefene or a pharmaceutically acceptable salt thereof are formulated for use in combination. The medicament is used for the prophylaxis or treatment of a substance-related disorder, preferably an alcohol-related disorder.
    Type: Grant
    Filed: August 13, 2020
    Date of Patent: May 9, 2023
    Assignees: Otsuka Pharmaceutical Co., Ltd., H. Lundbeck A/S
    Inventors: Kenji Maeda, Mai Nakamura
  • Treatment of headache using anti-CGRP antibodies
    Patent number: 11639381
    Abstract: Methods for immediate relief of migraine or headache are provided comprising the administration of an anti-CGRP antagonist antibody to a patient in need thereof.
    Type: Grant
    Filed: February 18, 2020
    Date of Patent: May 2, 2023
    Assignee: H. LUNDBECK A/S
    Inventors: Roger K. Cady, Jeffrey T. L. Smith, Joseph Hirman, Barbara Schaeffler, Lahar Mehta
  • Acute treatment and rapid treatment of headache using anti-CGRP antibodies
    Patent number: 11639380
    Abstract: Methods for rapid treatment of chronic migraine are provided. Exemplary methods provide relief from migraine within 24 hours of administration. Also provided are methods for acute treatment of migraine. Exemplary methods comprise administration of an anti-CGRP antagonist antibody to a patient in need thereof.
    Type: Grant
    Filed: January 8, 2020
    Date of Patent: May 2, 2023
    Assignee: H. LUNDBECK A/S
    Inventors: Roger K. Cady, Jeffrey T. L. Smith, Joseph Hirman, Barbara Schaeffler, Lahar Mehta
  • Combination treatments comprising administration of 1H-pyrazolo[4,3-b]pyridines
    Patent number: 11634416
    Abstract: The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (I) as PDE1 inhibitors together with a second compound which compound is useful in the treatment of a psychiatric disorder and their combined use as a medicament, in particular for the treatment of psychiatric and/or cognitive disorders.
    Type: Grant
    Filed: December 12, 2018
    Date of Patent: April 25, 2023
    Assignee: H. Lundbeck A/S
    Inventors: Jan Kehler, Karsten Juhl, Mauro Marigo, Paulo Jorge Vieira Vital, Mikkel Jessing, Morten Langgård, Lars Kyhn Rasmussen, Carl Martin Sebastian Clementson
  • Therapeutic uses of compounds having combined sert, 5-HT3 and 5-HT1a activity
    Patent number: 11628166
    Abstract: New pharmaceutical uses of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine and pharmaceutically acceptable salts thereof are provided.
    Type: Grant
    Filed: May 12, 2020
    Date of Patent: April 18, 2023
    Assignee: H. Lundbeck A/S
    Inventors: Nicholas Moore, Marianne Dragheim
  • PDE9 inhibitors with imidazo triazinone backbone and imidazo pyrazinone backbone for treatment of peripheral diseases
    Patent number: 11608342
    Abstract: The present invention relates to PDE9 inhibitors and their use for treatment of benign prostate hyperplasia and sickle cell disease.
    Type: Grant
    Filed: December 8, 2020
    Date of Patent: March 21, 2023
    Assignee: H. Lundbeck A/S
    Inventors: Niels Svenstrup, Kate Wen, Yazhou Wang
  • Fermentation process for antibody production
    Patent number: 11597758
    Abstract: A feedback control mechanism for a fermentation of yeast cells to make recombinant proteins uses a respiratory quotient measurement which adjusts the levels of oxygenation and/or fermentable sugar feed. The feedback control mechanism permits well controlled cultures that produce good amounts of product while avoiding toxic accumulation of ethanol. Additionally, recombinant proteins so produced have excellent qualitative properties, such as excellent homogeneity and proper inter-subunit assembly.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: March 7, 2023
    Assignee: H. LUNDBECK A/S
    Inventors: Gary Lesnicki, Patricia Dianne McNeill, Franz Hartner, Mark Young
  • Agent, uses and methods for treatment
    Patent number: 11548950
    Abstract: The present invention relates to monoclonal anti-Sortilin antibodies which have been found useful correcting a deficient level progranulin (PGRN). In particular, these antibodies can be used in the treatment of frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS).
    Type: Grant
    Filed: November 13, 2020
    Date of Patent: January 10, 2023
    Assignee: H. Lundbeck A/S
    Inventors: Lars Christian Biilmann Rønn, Ibrahim John Malik, Jeffrey B. Stavenhagen, Søren Christensen, Jan Egebjerg, Arnout Gerritsen, Edward van den Brink, Paul Parren, Rob de Jong
  • Alcohol derivatives as KV7 potassium channel openers
    Patent number: 11548849
    Abstract: The present invention provides novel compounds (e.g., compounds of Formula I) which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.
    Type: Grant
    Filed: July 30, 2020
    Date of Patent: January 10, 2023
    Assignee: H. Lundbeck A/S
    Inventors: Mario Rottlander, Xiaofang Wang, Debasis Das, Jian Hong, Shu Hui Chen, Anette Graven Sams, Krestian Larsen
  • Apparatus and method for isolation and/or preparation of particles
    Patent number: 11549871
    Abstract: An apparatus and a method for isolating and/or preparing particles are provided.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: January 10, 2023
    Assignee: H. Lundbeck A/S
    Inventors: Steen Sogaard, Tommy Carsten Lund Skovby, Asmus Ringlebjerg Mortensen, Jens Andersen Gad
  • Agents, uses and methods for the treatment of synucleinopathy
    Patent number: 11542323
    Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
    Type: Grant
    Filed: November 3, 2020
    Date of Patent: January 3, 2023
    Assignee: H. Lundbeck A/S
    Inventors: Pekka Kallunki, Karina Fog, Louise Buur Vesterager, Ann-Louise Bergstrôm, Florence Sotty, David Satijn, Edward Van Den Brink, Paul Parren, Rik Rademaker, Tom Vink, Ibrahim John Malik, Liliana Christina Pereira Montezinho, Jeffrey B Stavenhagen
  • Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors
    Patent number: 11535611
    Abstract: The present invention provides compounds of formula (I) that are PDE1 enzyme inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating disorders using the compounds of the invention.
    Type: Grant
    Filed: December 19, 2018
    Date of Patent: December 27, 2022
    Assignee: H. Lundbeck A/S
    Inventors: Jan Kehler, Lars Kyhn Rasmussen, Morten Langgård, Mikkel Jessing, Paulo Jorge Vieira Vital, Karsten Juhl, Mauro Marigo
  • Prodrugs of 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine and 4-((1R,3S)-6-chloro-3-(phenyl-d)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d)piperazine
    Patent number: 11535600
    Abstract: The present invention relates to prodrugs of 4-((1R,3S)-6-chloro-3-phenyl-2,3-dihydro-1H-inden-1-yl)-1,2,2-trimethylpiperazine in the form of 1a and 1b; and 4-((1R,3S)-6-chloro-3-(phenyl-d5)-2,3-dihydro-1H-inden-1-yl)-2,2-dimethyl-1-(methyl-d3)piperazine in the form of 2a and 2b, wherein X—is a counter ion, or pharmaceutically acceptable salts thereof. The present invention also provides pharmaceutical compositions comprising prodrugs, or pharmaceutically acceptable salts thereof, of the invention.
    Type: Grant
    Filed: November 27, 2019
    Date of Patent: December 27, 2022
    Assignee: H. Lundbeck A/S
    Inventors: Mikkel Fog Jacobsen, Morten Jørgensen
  • Injectable carbamazepine composition essentially free of 10-bromo-carbamazepine
    Patent number: 11529357
    Abstract: An injectable pharmaceutical composition comprising carbamazepine and sulfobutylether-7-?-cyclodextrin, wherein said composition is essentially free of 10-Br-carbamazepine, is disclosed. Methods for the manufacture of said composition and methods for treatment of disease using said composition are also disclosed.
    Type: Grant
    Filed: January 31, 2020
    Date of Patent: December 20, 2022
    Assignee: H. Lundbeck A/S
    Inventors: Hans Petersen, Jesper Tungelund Larsen
  • Agents, uses and methods for the treatment of synucleinopathy
    Patent number: 11524995
    Abstract: The invention relates to novel monoclonal anti-alpha-synuclein antibodies. The antibodies can be used for treating a synucleinopathy such as Parkinson's disease (including idiopathic and inherited forms of Parkinson's disease), Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy.
    Type: Grant
    Filed: June 8, 2020
    Date of Patent: December 13, 2022
    Assignee: H. Lundbeck A/S
    Inventors: Pekka Kallunki, Karina Fog, Louise Buur Vesterager, Ann-Louise Bergström, Florence Sotty, David Satijn, Edward van den Brink, Paul Parren, Rik Rademaker, Tom Vink, Ibrahim John Malik, Liliana Christina Pereira Montezinho, Jeffrey B. Stavenhagen
  • ALCOHOL DERIVATIVES AS KV7 POTASSIUM CHANNEL OPENERS
    Publication number: 20220380300
    Abstract: The present invention provides novel compounds which activate the Kv7 potassium channels. Separate aspects of the invention are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat disorders responsive to the activation of Kv7 potassium channels.
    Type: Application
    Filed: July 20, 2022
    Publication date: December 1, 2022
    Applicant: H. Lundbeck A/S
    Inventors: Mario Rottlander, Anette Graven Sams, Xiaofang Wang, Debasis Das, Jian Hong, Shu Hui Chen
  • 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
    Patent number: 11491140
    Abstract: The present invention provides 1H-pyrazolo[4,3-b]pyridin-7-amines of formula (1) as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
    Type: Grant
    Filed: July 30, 2020
    Date of Patent: November 8, 2022
    Assignee: H. Lundbeck A/S
    Inventors: Jan Kehler, Karsten Juhl, Mauro Marigo, Paulo Jorge Vieira Vital, Mikkel Jessing, Morten Langgård, Lars Kyhn Rasmussen, Carl Martin Sebastian Clementson
  • Imidazopyrazinones as PDE1 inhibitors
    Patent number: 11472810
    Abstract: The present invention provides imidazopyrazinones as PDE1 inhibitors and their use as a medicament, in particular for the treatment of neurodegenerative disorders and psychiatric disorders.
    Type: Grant
    Filed: October 26, 2020
    Date of Patent: October 18, 2022
    Assignee: H. Lundbeck A/S
    Inventors: Jan Kehler, Lars Kyhn Rasmussen, Morten Langgård, Mikkel Jessing, Karsten Juhl, Paulo Jorge Vieira Vital
  • 5-HT6 receptor antagonists for use in the treatment of alzheimer's disease in patient subpopulation carrying APOE4 alleles
    Patent number: 11464759
    Abstract: The present invention relates to 5-HT6 receptor antagonists for the treatment of Alzheimer's disease where the Alzheimer's disease patient carries one or two ApoE4 alleles comprising administering an effective dose of a 5-HT6 receptor antagonist to improve or augment the effect of an acetylcholinesterase inhibitor.
    Type: Grant
    Filed: May 23, 2018
    Date of Patent: October 11, 2022
    Assignee: H. Lundbeck A/S
    Inventor: Kristian Windfeld
  • Modulators of the NMDA receptor
    Patent number: 11466027
    Abstract: The present invention is directed to novel modulators of the NMDA receptor. Separate aspects of the inventions are directed to pharmaceutical compositions comprising said compounds and uses of the compounds to treat neurological disorders or neuropsychiatric disorders such as depression.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: October 11, 2022
    Assignee: H. Lundbeck A/S
    Inventors: John Paul Kilburn, Erhad Ascic, Mauro Marigo, Laurent David